Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydrochlorothiazide, quantity: 50 mg; amiloride hydrochloride dihydrate, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose monohydrate; magnesium stearate; povidone; wheat starch - amizide is indicated in the treatment of patients with: oedema of cardiac origin; hepatic cirrhosis with ascites; hypertension in whom potassium depletion might be anticipated. amizide, with its combination of amiloride hydrochloride and hydrochlorothiazide, minimizes the possibility of the development of excessive potassium loss in patients during vigorous diuresis for prolonged periods. amizide, with it's built in potassium sparing agent, is especially indicated in those conditions where the positive effect on potassium balance is particularly important. hypertension. amizide may be used alone or as an adjunct to other anti-hypertensive drugs. since it enhances the action of these agents, the dosage of these antihypertensive drugs may need to be reduced to avoid the risk of an excessive drop in blood pressure.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dosulepin (dothiepin) hydrochloride, quantity: 75 mg - tablet, film coated - excipient ingredients: povidone; maize starch; sodium starch glycollate; lactose monohydrate; purified talc; magnesium stearate; titanium dioxide; xanthan gum; polyvinyl alcohol; brilliant scarlet 4r; lecithin - the 75mg tablets are indicated only for the maintenance treatment of major depression. (see precautions).

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; polysorbate 80; hypromellose; colloidal anhydrous silica; mannitol; sodium starch glycollate type b; povidone; titanium dioxide; iron oxide red; macrogol 3350; carnauba wax; iron oxide black - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; polysorbate 80; sodium starch glycollate type b; hypromellose; colloidal anhydrous silica; magnesium stearate; mannitol; iron oxide red; iron oxide yellow; titanium dioxide; carnauba wax; macrogol 3350 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: povidone; hypromellose; colloidal anhydrous silica; mannitol; polysorbate 80; sodium starch glycollate type b; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; carnauba wax; macrogol 3350 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sotalol hydrochloride, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; hyprolose; magnesium stearate; colloidal anhydrous silica - prevention and treatment of supraventricular and ventricular arrhythmias.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000; iron oxide black - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000; iron oxide black - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.